Application of Endoscopic Scissors Cutting ENBD Tube in the Treatment of Malignant Hilar Biliary Strictures

Sponsor
Changhai Hospital (Other)
Overall Status
Withdrawn
CT.gov ID
NCT03353181
Collaborator
First People's Hospital of Hangzhou (Other), First Affiliated Hospital Xi'an Jiaotong University (Other), Fuzhou General Hospital (Other), LanZhou University (Other), Zhejiang University (Other), Chengdu PLA General Hospital (Other), The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (Other), General Hospital of Beijing PLA Military Region (Other), Dongfang Hospital Beijing University of Chinese Medicine (Other), Peking Union Medical College Hospital (Other), ShuGuang Hospital (Other), Eastern Hepatobiliary Surgery Hospital (Other), Xijing Hospital (Other)
0
1
2
24.8
0

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate application value of the endoscopic cutting technique in the treatment of malignant hilar biliary strictures.

Condition or Disease Intervention/Treatment Phase
  • Device: Endoscopic scissors
  • Device: Biliary stent
N/A

Detailed Description

The management unresectable malignant hilar biliary strictures is still very difficult in spite of the rapid development of new endoscopic devices.The application of stent (plastic or metallic) has allowed us to achieve successful drainage. However,there are many complications related to the placement of stents,such as cholangitis,high rate of re-intervention,and so on. The application of endoscopic cutting technique is considered to reduce these complication.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Parallel AssignmentParallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Application of Endoscopic Scissors Cutting Endoscopic Nasobiliary Drainage Tube in the Treatment of Malignant Hilar Biliary Strictures: a Multicenter, Prospective, Randomized Controlled Study
Actual Study Start Date :
Nov 30, 2017
Actual Primary Completion Date :
Sep 25, 2019
Actual Study Completion Date :
Dec 25, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Endoscopic scissors

Endoscopic nasobiliary drainage for malignant hilar biliary strictures at first, and application of endoscopic cutting technique followed.

Device: Endoscopic scissors
Application of endoscopic cutting technique following endoscopic nasobiliary drainage in the treatment of malignant hilar biliary strictures.

Active Comparator: Stent

Standard placement of biliary stent for malignant hilar biliary strictures.

Device: Biliary stent
Standard placement of biliary stent

Outcome Measures

Primary Outcome Measures

  1. occurrence of acute cholangitis [30 days]

    Acute cholangitis is defined as cholangitis that occurred within 30 days after endoscopic retrograde cholangiopancreatography(ERCP).

Secondary Outcome Measures

  1. Clinical success [30 days]

    Clinical success was defined as a decrease in the total bilirubin level to ≤50% of the pretreatment value within 1 week or to ≤75% within 4 weeks.

  2. Re-intervention [6 months]

    Re-intervention was defined as any type of endoscopic or percutaneous procedure necessary to improve biliary drainage for jaundice or cholangitis after successful placement.

Other Outcome Measures

  1. early adverse [30 days]

    Early adverse event was defined as any ERCP-related adverse event within 4 weeks and a late event was defined as one that occurred after 4 weeks.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients age over 18 and able to tolerate ERCP.

  2. Pathologically confirmed inoperable malignant hilar biliary strictures of Bismuth type II to IV.

  3. No history of biliary tract surgery and first attempt at endoscopic or percutaneous drainage.

  4. No acute cholangitis before ERCP.

  5. Informed consent.

Exclusion Criteria:
  1. The patient is very ill(Septic shock, sepsis,coagulation disorders and so on) and cannot tolerate endoscopic treatment.

  2. Previous biliary drainage procedure.

  3. Inability to provide informed consent.

  4. Participating in other clinical trials.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Gastroenterology, Changhai Hospital, Second Military Medical University Shanghai Shanghai China 200433

Sponsors and Collaborators

  • Changhai Hospital
  • First People's Hospital of Hangzhou
  • First Affiliated Hospital Xi'an Jiaotong University
  • Fuzhou General Hospital
  • LanZhou University
  • Zhejiang University
  • Chengdu PLA General Hospital
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
  • General Hospital of Beijing PLA Military Region
  • Dongfang Hospital Beijing University of Chinese Medicine
  • Peking Union Medical College Hospital
  • ShuGuang Hospital
  • Eastern Hepatobiliary Surgery Hospital
  • Xijing Hospital

Investigators

  • Principal Investigator: Zhaoshen Li, M.D, Changhai Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Zhaoshen Li, Director of Gastroenterology Dept, Changhai Hospital
ClinicalTrials.gov Identifier:
NCT03353181
Other Study ID Numbers:
  • ENBD-01
First Posted:
Nov 27, 2017
Last Update Posted:
Aug 25, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Zhaoshen Li, Director of Gastroenterology Dept, Changhai Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 25, 2022